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LETTER TO THE EDITOR
Comment on “The Clinical Features and 
Pathophysiology of Acute Radiation Dermatitis in 
Patients Receiving Tomotherapy”
Slav Yartsev, Ph.D., Edward Yu, M.D.
London Regional Lancer Program, London Health Sciences Centre, London, Ontario, Canada
Dear Editor:
We read with interest the article by Lee et al.
1, where a 
significantly more severe dermatitis was reported in 
patients receiving tomotherapy when compared to 
patients receiving conventional radiation. However, the 
authors do not provide any reasons for their findings. 
Unfortunately, there is no information on contouring of 
the planning target volume (PTV); therefore, we can only 
speculate that grade 2 dermatitis in breast cancer patients 
might occur due to inclusion of voxels with low computer 
tomography (CT) numbers (air) as the target. Low density 
materials are less attenuating and require higher intensity 
of radiation for delivery of the same dose as to more dense 
tissues.  If this is the case, the actual dose delivered to the 
surface layer might be higher than the prescription. In our 
institution, tomotherapy has been used clinically since 
September 2004, and we have not observed serious der-
matitis in our tomotherapy patients, compared to “conven-
tional” techniques. In order to verify the correspondence 
of calculated and actually delivered doses, either MOSFET 
dosimeters OneDose
TM (Sicel Technologies, Morrisville, 
NC)
2 or optically stimulated luminescence (OSL) dosime-
ters InLight
Ⓡ NanoDot
TM (Landauer Inc., Glenwood, IL)
3 
are used during the first fraction of the treatment for 
lesions close to the surface.
To stress the importance of careful contouring of the target 
and planning, we refer to one of our recent cases 
involving a 73-year-old male with a history of squamous 
cell carcinoma (SCC) on his scalp since 2004. He had 
undergone at least two surgical excisions with skin flaps in 
2006 and 2008. He has had multiple recurrences of these 
lesions, mainly around flaps involving a large area of his 
scalp. The patient refused additional surgical procedures.  
He underwent photodynamic therapy (PDT) in 2007 for 
treatment of actinic keratosis of his scalp as an attempt at 
possible control of his SCC. However, due to skin irrita-
tion and pain from treatment, the patient did not tolerate 
PDT.  Tomotherapy treatment was recommended in order 
to avoid critical organs, such as optic nerves, lens, and 
brain tissue. He underwent CT simulation and planning 
for tomotherapy treatment of his scalp lesion of 60 Gy in 
1.8 Gy fractions over a period of 6 ½ weeks, resulting in 
the dose-volume histogram shown in Fig. 1A with good 
sparing of organs at risk. The PTV was contoured 2 mm 
below the surface in order to avoid air voxels in the target 
volume, as shown in Fig. 1B together with the planned 
dose distribution. During the course of tomotherapy, 
grade 1 radiation dermatitis developed after 4 weeks into 
treatment. The treating physician reviewed this patient 
during his course of treatment and recommended a skin 
moisturizing gel (hypo-allergenic Aloe Vera). Dry skin 
desquamation was observed in the irradiated area of the 
scalp during the last week of the therapy. He tolerated the 
course of the therapy without any treatment interruption. 
Two months after tomotherapy, the patient showed a 
clinically complete response, as shown in Fig. 2, and 
recovered from radiation dermatitis on follow-up assess-
ment. To date, 5 months after completion of tomotherapy  
the patient has shown no disease recurrence. MRI of the S Yartsev and E Y
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Fig. 1. (A) Cumulative relative dose-volume histogram and (B) dose distribution for the patient with large superficial target volume.
GTV: gross tumor volume, PTV: planning target volume, unlabeled dose-volume histograms correspond to the right eye (purple), right lens
(blue), right optic nerve (orange), optic chiasm (green), spinal cord (yellow). 
Fig. 2. Clinical photographs of the 
patient’s scalp: (A) before and (B) 2 
months after tomotherapy treatment.
brain showed no acute radiation effect on brain tissue. 
This example, with a very large superficial target, shows 
that careful contouring of targets close to the skin surface 
is necessary in order to avoid significant dermatitis.
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